Cargando…
Pathophysiology of ischemia reperfusion injury and use of fingolimod in cardioprotection /
Pathophysiology of Ischemia-Reperfusion Injury and Use of Fingolimod in Cardioprotection is a deep examination into the mechanisms of myocardial ischemiareperfusion injury and role of fingolimod as a cardioprotective agent through its antioxidant, anti-apoptotic and anti-inflammatory effects. Dr. Ah...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press, an imprint of Elsevier,
[2019]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1103605858 | ||
| 003 | OCoLC | ||
| 005 | 20231120010356.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 190605s2019 enkab ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d EBLCP |d OPELS |d UKMGB |d OCLCF |d UKAHL |d OCLCQ |d ERF |d LVT |d UX1 |d VT2 |d OCLCO |d OCLCA |d YDX |d OCLCQ |d OCLCO |d COM |d OCL |d OCLCQ |d SFB |d OCLCQ |d OCLCO | ||
| 015 | |a GBB9A9290 |2 bnb | ||
| 016 | 7 | |a 019433959 |2 Uk | |
| 019 | |a 1229500265 |a 1235822477 | ||
| 020 | |a 9780128182536 |q (electronic bk.) | ||
| 020 | |a 0128182539 |q (electronic bk.) | ||
| 020 | |a 9780128180235 |q (electronic bk.) | ||
| 020 | |a 0128180234 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1103605858 |z (OCoLC)1229500265 |z (OCoLC)1235822477 | ||
| 050 | 4 | |a RB144.5 | |
| 060 | 4 | |a 2019 F-778 | |
| 060 | 4 | |a WG 282 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.1/3 |2 23 |
| 100 | 1 | |a Ahmed, Naseer, |e author. | |
| 245 | 1 | 0 | |a Pathophysiology of ischemia reperfusion injury and use of fingolimod in cardioprotection / |c Naseer Ahmed. |
| 264 | 1 | |a London : |b Academic Press, an imprint of Elsevier, |c [2019] | |
| 300 | |a 1 online resource : |b illustrations, map | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed June 06, 2019). | |
| 520 | |a Pathophysiology of Ischemia-Reperfusion Injury and Use of Fingolimod in Cardioprotection is a deep examination into the mechanisms of myocardial ischemiareperfusion injury and role of fingolimod as a cardioprotective agent through its antioxidant, anti-apoptotic and anti-inflammatory effects. Dr. Ahmed explore the physiology and pathophysiology of myocardial metabolism under normal and ischemic conditions and focused on pharmacological cardioprotection. They provide a concise, yet rigorous discussion of Ischemia-Reperfusion Injury, Myocardial Ischemia during Circulatory Arrest, Myocardial Reperfusion, Myocardial Protection related to Ischemia-Reperfusion Injury and Role of Fingolimod in Cardioprotection. Pathophysiology of Ischemia-Reperfusion Injury and Use of Fingolimod in Cardioprotection is ideal for researchers, cardiovascular scientists, and clinical pharmacologists to further work in this challenging area and apply this knowledge to clinical trials for cardioprotection. | ||
| 650 | 0 | |a Reperfusion injury |x Pathophysiology. | |
| 650 | 0 | |a Ischemia. | |
| 650 | 0 | |a Immunosuppressive agents. | |
| 650 | 0 | |a Coronary heart disease. | |
| 650 | 1 | 2 | |a Myocardial Reperfusion Injury |x physiopathology |0 (DNLM)D015428Q000503 |
| 650 | 2 | 2 | |a Fingolimod Hydrochloride |x therapeutic use |0 (DNLM)D000068876Q000627 |
| 650 | 2 | 2 | |a Myocardial Ischemia |0 (DNLM)D017202 |
| 650 | 2 | |a Ischemia |0 (DNLM)D007511 | |
| 650 | 2 | |a Immunosuppressive Agents |0 (DNLM)D007166 | |
| 650 | 6 | |a L�esions de reperfusion |0 (CaQQLa)201-0262409 |x Physiopathologie. |0 (CaQQLa)201-0379296 | |
| 650 | 6 | |a Isch�emie. |0 (CaQQLa)201-0045126 | |
| 650 | 6 | |a Immunosuppresseurs. |0 (CaQQLa)201-0072474 | |
| 650 | 6 | |a Isch�emie myocardique. |0 (CaQQLa)201-0293856 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Coronary heart disease |2 fast |0 (OCoLC)fst00879535 | |
| 650 | 7 | |a Immunosuppressive agents |2 fast |0 (OCoLC)fst00968037 | |
| 650 | 7 | |a Ischemia |2 fast |0 (OCoLC)fst00979713 | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128180235 |z Texto completo |